Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-06-17
2008-06-17
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S259200, C540S229000, C544S279000, C544S280000
Reexamination Certificate
active
07388005
ABSTRACT:
The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2alkyl group and a hydrogen atom; y represents a bond, an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a nitrogen atom being optionally; or a methylene group optionally substituted; R1 represents a pyrimidine group optionally substituted; R2 may represent a C1-6alkyl group optionally substituted by a C6,10aryloxy or a C6,10arylamino group; a C3-6cycloalkyl group, a C1-4alkylthio group, a C1-4alkoxy group, a C1-2perhalogenated alkyl group, a C1-3halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represents each independently a hydrogen atom, C1-6alkyl group, a hydroxy group, a C1-4alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6alkyl group or a halogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β3 or GSK3β3 and cdk5/p25, such as Alzheimer disease.
REFERENCES:
patent: 2804959 (2001-08-01), None
patent: WO 98/16528 (1998-04-01), None
patent: WO 98/24780 (1998-06-01), None
patent: WO 01/44246 (2001-06-01), None
Wagman (Curr. Pharm. Des., 2004, 10, 1105-1137).
NINDS Index, Disorders Index of the National Institute of Neurological Disorders and Stroke, http://www.ninds.nih.gov/disorders/disorder—index.htm?css=print.
Bhat, et al., J. Neurochem., 2004, 89, 1313-1317.
Martinez, et al., Med. Res. Rev., vol. 22, No. 4, 373-384 (2002).
Buée, et al., Brain Res. Rev., 33 (2000) 95-130.
Henriksen, et al., Curr. Drug Targets, 2006, 7 (11), 1435-42 (Abstract).
Gould et al., Curr. Drug Targets, Nov. 7, 2006(11): 1399-409 (Abstract).
Harwood, Curr. Mol. Med., Aug. 2003; 3(5): 472-82 (PubMed abstract).
Zhao, et al., Schizophr. Res., May 2006; 84(1). Epub Apr. 11, 2006 (Abstract).
Gould, Expert Opin. Ther. Targets, Jun. 2006; 10(3):377-92 (Abstract).
Kwok, et al., Annals of Neurology, vol. 58, No. 6, Dec. 2005, pp. 829-839.
Nadri, et al., Schizophrenia Research, 71 (2004), 377-382.
Derwent Patent Abstract No. 200157 (2004).
Gallet Thierry
Lardenois Patrick
Lochead Alistair
Marguerie Séverine
Nedelec Alain
Berch Mark L.
Gupta Balaram
Jaisle Cecilia M
Mitsubishi Pharma Corporation
Sanofi-Aventis
LandOfFree
Substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2798471